Novella Clinical has named Catherine Tyner as its new executive director, oversight group management.
She joins the contract research organisation (CRO) in time for the expansion of its integrated design and implementation of clinical oversight groups services.
Prior to Novelle, Tyner has worked in CRO oversight for more than 250 trials spanning phases I-IV and a wide number of indications.
“The use and requirements of oversight groups are complex and dynamic – especially when multiple groups are utilized on the same trial,” said Tyner.
“Many Sponsors will benefit from experienced guidance in navigating, integrating and optimizing these processes.”
Roche has appointed Hyam Levitsky as head of cancer immunology experimental medicine.
Levitsky was previously professor of oncology, medicine and urology at the Johns Hopkins University School of Medicine.
He will become a new member of the pharma research and early development (pRED) team.
Michael Burgess, global head of oncology discovery and translational area at Roche, said: "With his extensive and wide-ranging academic and medical research background, we believe he is uniquely qualified to bring new and different perspectives to the pRED Oncology organization and look forward to utilizing his expertise to develop differentiated cancer medicines that are beneficial for patients and healthcare providers."
Jostein Davidsen has become head of emerging markets at Nycomed.
Nycomed – who were recently acquired by Takeda because of its presence in the emerging markets – says the new appointment further consolidates its commitment to working within developing countries.
Davidsen also retains his role as area head of Russia/CIS.
Frank Morich, executive VP of international operations in the Americas and Europe of Takeda Pharmaceuticals International and CEO of Nycomed said: “His extensive knowledge of the industry, combined with vision and tenacity, has propelled Russia/CIS to become one of Nycomed’s top revenue contributors.”
CTI Clinical Trial and Consulting Services has employed John Edwards as medical director.
Prior to CTI, Edwards – who specialises in umbilical cord blood stem cells – served as present, COO and CMO of Lifeforce Cryobanks. He was also the Founding medical director of the Florida Hospital Cancer Institute bone marrow transplant program.
Lynn Fallon, executive VP and president of consulting services at CTI said: “We are pleased to have him join our Medical Affairs Team to enable us to expand our licensing and acquisition, drug development, and clinical trial services to current and future clients.”
Sarah Landfield has become VP of pharmaceutical markets at Healthcare Regional Marketing (HRM).
She joins the firm from AgencyRx, where she was VP and account supervisor.
In her new position Landfield will be responsible for developing and executing strategy as well as managing long-term client relationships.